Wednesday, November 10, 2021 at 2pm EST | 1pm CST | 11am PST Western honey bees ingesting phytocannabinoid-rich extracts produce pharmacologically active cannabinoid metabolites in their raw honey. These metabolites enhance the pharmacokinetic profile of cannabidiol in human and rodent models.
Register Free: https://www.chromatographyonline.com/lcgc_w/honey_bees
Event Overview:
Currently, there is a U.S patent granted for the process of administering high-CBD hemp extract to Western honey bees (Apis mellifera) through their food; the process results in raw honey infused with low milligram quantities of phytocannabinoids. The Western honey bee possesses several isoforms of CYP450 enzymes, CYP6 and CYP9, which are responsible for the oxidative metabolism of flavonoids, nicotine, and other xenobiotics consumed by bees. Based upon published pharmacokinetic studies, CBD is metabolized by CYP450 enzymes into both 7-COOH-CBD (MW: 344.44) and 7-OH-CBD (MW: 330.5). The resulting honey possesses both primary and secondary CBD metabolites, 7-OH-CBD and 7-COOH-CBD, respectively, along with untransformed phytocannabinoids from the fed extract.
Key Learning Objectives:
Who Should Attend:
Speakers
Edward A. Palumbo II
Senior R&D Scientist
Charlotte's Web Inc.
My research interests are focused on natural products and medicinal chemistry. As an R&D Scientist, I have worked with multi-disciplinary teams in quality management, marketing, manufacturing, product development, and process engineering to create innovative products in the dietary supplement industry. I have ample experience developing and validating analytical methods to monitor manufacturing processes at cGMP facilities, while using DoE and QbD to minimize testing and experimentation costs.
Outside of our laboratory, I guide preclinical & clinical research initiatives with academic research partners & CROs, while initiating safety studies required by regulatory agencies, domestic & abroad. I understand the regulatory challenges and hurdles posed by acquiring GRAS status, navigating the U.S FDA IND process, and gaining access to international nutraceutical markets. My goal is to demonstrate the scientific merit of dietary supplement use, while driving research initiatives to generate insightful PK and PD data on novel hemp formulations. Ultimately, I aim to minimize costs and maximize return on investment through technically-driven product development strategies coupled with collaborative research.
Register Free: https://www.chromatographyonline.com/lcgc_w/honey_bees